Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to developing a completely in situ immunotherapy platform optimized for solid tumor cancers that combines partial oncolysis and a multi-target biologic drug infusion. The platform is designed to achieve personalized T cell activation, empowering the immune system to recognize and attack cancer throughout the body.  The first 2 candidates, SV-101 and SV-102 are currently in Phase 1 trials.